You are here: Industry Insights > cardiovascular diseases

News List

Active Ingredients of Salviae Miltiorrhizae and Their Current Research Status in Cardiovascular Diseases Xiaonisha
August 08, 2025
Salviae Miltiorrhizae, the dried roots and rhizomes of the Salvia genus in the Labiatae family, is a commonly used traditional Chinese medicine for promoting blood circulation and removing blood stasis.
Research Progress on the Target GDF15 Signaling Pathway and Related Drugs Xiaonisha
July 25, 2025
Growth differentiation factor 15 (GDF15), identified and discovered from activated macrophage lineage clones, functions as an autocrine regulatory molecule in macrophages and serves as an endocrine hormone.
Research Progress on the Pharmacological Effects of Salvianolic Acid B in Cardiovascular Diseases Xiaomichong
July 04, 2024
Sal B is a water-soluble component extracted from Danshen (Salvia miltiorrhiza). It is a phenolic acid compound formed by the condensation of 3 molecules of danshensu and 1 molecule of caffeic acid.
Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study Biotech Newswire
August 28, 2024
Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.
Windtree Therapeutics and CVie Therapeutics Announce Merger to Create a Global Acute Care Company pharmafocusasia
December 24, 2018
Windtree Therapeutics, Inc., a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, and CVie Investments Limited (CVie).....